• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
EuroBioForum 2013 - Day 1 | Horst Domdey
 

EuroBioForum 2013 - Day 1 | Horst Domdey

on

  • 389 views

EuroBioForum 2013 2nd Annual Conference ...

EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013

=======================================

# KEYNOTE PRESENTATION #

m4 -> P4

Dr Horst Domdey
Managing Director at BioM
(co-host of EuroBioForum 2nd Annual Conference 2013)

=======================================

http://www.eurobioforum.eu

Statistics

Views

Total Views
389
Views on SlideShare
383
Embed Views
6

Actions

Likes
0
Downloads
2
Comments
0

1 Embed 6

http://www.eurobioforum.eu 6

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    EuroBioForum 2013 - Day 1 | Horst Domdey EuroBioForum 2013 - Day 1 | Horst Domdey Presentation Transcript

    • www.m4.dem4 g P4Horst DomdeyBioM
    • www.m4.deClusterManagementfor MunichHospitalsin MunichBiotechand Pharmain MunichSciencein MunichPersonalized Medicine in Munich€ 100 MProgramonPersonalizedMedicine
    • www.m4.deIn June 2012 Corimmunwas acquired by Jansen-CilagCOR-1 is a cyclic peptidewhich neutralizesstimulatory autoimmuneantibodies directed againstthe beta-adrenergic receptormimicking the effect ofnatural ligands likeadrenaline and thus leadingto a chronic over-stimulationof the receptor.Consequently this leads tohypertrophy and reducedfunction of the heart.• Ex vivo, COR-1 showed goodefficacy to neutralize anti ß1receptor autoantibodies.• In animal models, COR-1prevented the generation of heartfailure and also reversed existingheart failure.• In a placebo-controlled phaseI clinical trial COR-1 was shownto be well tolerated.• COR-1 is now being investigatedin a phase II clinical trial; it isadministered to a subgroup ofheart failure patients who havebeen stratified by a specificdiagnostic test.COR-1 – an m4 Lighthouse Project
    • www.m4.dem4 Scouting & Incubation• m4 ScoutingIdentification of (bio)pharmaceutical researchprojects with a high innovationspotentia• m4 AwardRegional pre-seed program for innovativeresearch projects in the field of biomarkersand drug development• m4 Mentor CircleProfessional mentoring by retired experts fromacademia and industry• m4 IncubationAssisted incubation of the m4 Award projects
    • www.m4.dePredictiveBiomarkers- DNA/RNA-omics- ProteomicsP4 Medicine – Healthcare of the FuturePersonalizedStratification of Patients- Herceptin- Erbitux- . . .PreventiveLife Style and Treatment- Phenylketonuria- Diabetes- CancerParticipatoryInformed Decisionsby informed Patients- 1000$ Genome
    • www.m4.de4 Challenges1. Health Economics2. Alternative individualized treatments3. Biomarkers4. IT